Perceptive Advisors LLC
recently stated that they own 5.3% of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in a Schedule 13G disclosure that was filed with the Securities and Exchange Commission on Friday, September 8th. The investor owns 4,657,589 shares of the stock valued at $264,970,238. The reporting parties listed on the disclosure included Perceptive Advisors LLC, Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd. The filing is available through EDGAR at this hyperlink.
Other large investors also recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company increased its stake in Neurocrine Biosciences by 7.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock worth $123,000 after purchasing an additional 193 shares in the last quarter. First Mercantile Trust Co. increased its stake in Neurocrine Biosciences by 22.2% during the 1st quarter. First Mercantile Trust Co. now owns 3,082 shares of the company’s stock worth $133,000 after purchasing an additional 560 shares in the last quarter. ARS Investment Partners LLC bought a new stake in Neurocrine Biosciences during the 2nd quarter worth approximately $207,000. Stephens Inc. AR bought a new stake in Neurocrine Biosciences during the 2nd quarter worth approximately $207,000. Finally, Capstone Asset Management Co. bought a new stake in Neurocrine Biosciences during the 1st quarter worth approximately $214,000.
Several equities analysts have recently weighed in on the stock. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and set a $70.00 price target on shares of Neurocrine Biosciences in a research note on Thursday, September 7th. ValuEngine raised shares of Neurocrine Biosciences from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Piper Jaffray Companies set a $68.00 target price on shares of Neurocrine Biosciences and gave the company a “buy” rating in a research note on Thursday, August 24th. Cowen and Company reissued an “outperform” rating and issued a $65.00 target price (up from $60.00) on shares of Neurocrine Biosciences in a research note on Wednesday, August 9th. Finally, BidaskClub raised Neurocrine Biosciences from a “hold” rating to a “buy” rating in a report on Wednesday, August 9th. Two analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $68.25.
ILLEGAL ACTIVITY NOTICE: “5.3% Stake of Neurocrine Biosciences, Inc. (NBIX) Maintained by Perceptive Advisors LLC” was first posted by BBNS and is the sole property of of BBNS. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://baseballnewssource.com/markets/5-3-stake-of-neurocrine-biosciences-inc-nbix-held-by-perceptive-advisors-llc/1603457.html.
Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) traded up 0.42% during trading on Friday, reaching $57.15. The company’s stock had a trading volume of 186,973 shares. The stock’s 50 day moving average price is $53.72 and its 200-day moving average price is $48.84. The stock’s market cap is $5.04 billion. Neurocrine Biosciences, Inc. has a 52-week low of $37.35 and a 52-week high of $60.00.
Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Thursday, August 3rd. The company reported ($0.68) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.01). The firm had revenue of $6.34 million during the quarter, compared to analysts’ expectations of $0.61 million. During the same period in the prior year, the company earned ($0.46) EPS. Equities analysts anticipate that Neurocrine Biosciences, Inc. will post ($2.45) EPS for the current year.
In related news, insider Haig P. Bozigian sold 22,500 shares of the business’s stock in a transaction dated Friday, August 4th. The stock was sold at an average price of $50.00, for a total value of $1,125,000.00. Following the sale, the insider now directly owns 154,601 shares in the company, valued at $7,730,050. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Christopher Flint Obrien sold 8,734 shares of the company’s stock in a transaction that occurred on Thursday, July 27th. The shares were sold at an average price of $50.00, for a total value of $436,700.00. Following the sale, the insider now owns 57,707 shares in the company, valued at $2,885,350. The disclosure for this sale can be found here. Insiders sold 125,655 shares of company stock valued at $7,018,148 in the last ninety days. 4.80% of the stock is currently owned by corporate insiders.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with our FREE daily email newsletter.